The Latest Analyst Ratings for UroGen Pharma
Portfolio Pulse from Benzinga Insights
In the last quarter, UroGen Pharma (NASDAQ:URGN) received 3 bullish ratings and 1 indifferent rating from analysts. The company's average 12-month price target has increased by 164.71% from $17.00 to $45.00.
October 04, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UroGen Pharma received positive analyst ratings, which could boost investor confidence and potentially increase the stock price.
Analyst ratings often influence investor sentiment. In this case, UroGen Pharma received mostly bullish ratings, which could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100